Polymerase chain reaction-based "pre-emptive" therapy with cidofovir for cytomegalovirus reactivation in allogeneic hematopoietic stem cells transplantation recipients: A prospective study

Haematologica

Volumn 87, Issue 4, 2002, Pages 446-447

  Bosi, Alberto ^a   Bartolozzi, Benedetta ^a   Vannucchi, Alessandro M ^a   Orsi, Alessandra ^a   Guidi, Stefano ^a   Rossi Ferrini, Pierluigi ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cidofovir; CMV; Hematopoietic stem cell transplantation; PCR; Pre emptive therapy

Indexed keywords

ACICLOVIR; CIDOFOVIR; CREATININE; FOSCARNET SODIUM; GANCICLOVIR; PROBENECID; STEROID; VIRUS DNA;

ADULT; ALLOGRAFT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DRUG CHOICE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; NEPHROTOXICITY; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PROPHYLAXIS; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REACTIVATION; VIRUS TRANSMISSION;

ADULT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOSINE; DNA, VIRAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; VIRUS ACTIVATION;

EID: 0036218049     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients
2. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR
3. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive therapy in allogeneic bone marrow transplant recipients
4. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: Risk factors and outcome
5. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients
6. Clinical use of cidofovir
7. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients
8. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections
9. Successful pre-emptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation